

FORM PTO-1390 (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 515-4204	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.6) 09/622146	
INTERNATIONAL APPLICATION NO. PCT/EP99/01191		INTERNATIONAL FILING DATE 24 February 1999		PRIORITY DATE CLAIMED 25 February 1998	
TITLE OF INVENTION SULPHATED HYALURONIC ACID AND SULPHATED DERIVATIVES THEREOF COVALENTLY BOUND TO POLYURETHANES, AND THE PROCESS FOR THEIR PREPARATION					
APPLICANT(S) FOR DO/EO/US Rolando BARBUCCI; Marco CONSUMI; Agnese MAGNANI; and Lanfranco CALLEGARO					

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
 International Search Report and cited documents;
 Report of International Preliminary Examining Authority with annexes;
 Copy of PCT Request;
 Copy of PCT Form IB/308 and IB/332; and
 Form PTO-1449

01/17/2001 09:00:00 00000023 081540 09622146

01 FC:118 1390.00 CH


CERTIFICATE OF MAILING BY "EXPRESS MAIL"


"EXPRESS MAIL" MAILING LABEL NUMBER EL473773143US

DATE OF DEPOSIT August 11, 2000

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE BY "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO BOX PCT, ASST. COMMISSIONER OF PATENTS, WASHINGTON, D.C. 20231

PRINTED NAME: JAMES V. COSTIGAN

SIGNATURE: 

U.S. APPLICATION NO. (if known) 09/622146		INTERNATIONAL APPLICATION NO. PCT/EP99/01191		ATTORNEY'S DOCKET NUMBER 515-4204	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input checked="" type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	19 - 20 =	0	X \$18.00	\$ 0	
Independent claims	3 - 3 =	0	X \$78.00	\$ 0	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		0	+ \$260.00	\$ 0	
TOTAL OF ABOVE CALCULATIONS =				\$ 970.00	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$ 0	
SUBTOTAL =				\$ 970.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$ 970.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 0	
TOTAL FEES ENCLOSED =				\$ 970.00	
				Amount to be:	\$
				refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>970.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>08-1540</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: JAMES V. COSTIGAN, ESQ. HEDMAN, GIBSON & COSTIGAN, P.C. 1185 AVENUE OF THE AMERICAS, SUITE 2003 NEW YORK, NY 10036-2646 212-302-8989					
				 SIGNATURE:	
				JAMES V. COSTIGAN	
				NAME	
				25,669	
				REGISTRATION NUMBER	

09/622146

Docket No.: 515-4204

534 Rec'd PCT/PTO 11 AUG 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT OPERATION

In re Application of:)
)
Rolando BARBUCCI)
Marco CONSUMI)
Agnese MAGNANI)
Lanfranco CALLEGARO) Group Art Unit: --
)
Serial No.: Not Yet Assigned) Examiner: --
)
Filed: Concurrently Herewith)
)
For: SULPHATED HYALURONIC ACID AND SULPHATED DERIVATIVES
THEREOF COVALENTLY BOUND TO POLYURETHANES, AND THE
PROCESS FOR THEIR PREPARATION

New York, NY 10036
August 11, 2000

Box PCT
Assistant Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

SIR:

Prior to examination, kindly amend the above-
identified application, as follows:


CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NO.: EL473773143US
Date of Deposit: August 11, 2000

I hereby certify that this paper or fee is being
deposited with the United States Postal Service by
"Express Mail Post Office to Addressee" Service
under 37 CFR 1.10 on the date indicated above and is
addressed to:

Box PCT
Assistant Commissioner for Patents
Washington, DC 20231

James V. Costigan, Registration No. 25,669
(Typed or Printed Name of Person Mailing)


(Signature of Person Mailing Paper or Fee)

IN THE CLAIMS

Kindly amend claims 3, 4, 6, 9, 10, 13, 17 and 18 under the provisions of 37 CFR§1.121(a) by deleting the bracketed subject matter and inserting the underlined material:


3. (amended) The polyurethane according to [any of] claim[s] 1 [and 2], wherein the starting sulphated hyaluronic acid is selected from the group consisting of:

- A₁) O-sulphated hyaluronic acid, and
- B₂) N-sulphated hyaluronic acid.


4. (amended) The polyurethane according to [any of] claim[s] 1 [and 2], wherein the starting sulphated hyaluronic acid derivative is selected from the group consisting of:

- A₂) O-sulphated hyaluronic acid derivative, and
- B₂) N-sulphated hyaluronic acid derivative.

6. (amended) The polyurethane according to [any of] claim[s] 1[-5] of formula (1)



or formula (II)



wherein PU is a residue of the polyurethane chain, Hsulph is a residue of the sulphated hyaluronic acid or a sulphated hyaluronic acid derivative containing at least one free carboxylic function.

9. (amended) Haemocompatible material comprising at least one polyurethane according to [any of] claim[s] 1[-6].

10. (amended) Haemocompatible material consisting of at least one polyurethane according to [any of] claim[s] 1[-6].

13. (amended) The haemocompatible material according to [any of] claim[s] 9[, 11 and 12], further comprising at least one natural, synthetic or semisynthetic polymer.

17. (amended) The haemocompatible material according to [any of] claim[s] 9[-16], in the form of sponges, films, membranes, threads, tampons, non-woven fabrics, microspheres, nanospheres, gauzes, gels and guide channels.


18. (amended) Industrial or medical articles or devices made with or coated with the haemocompatible material according to [any of] claim[s] 9[-16].

REMARKS

This Amendment is being to delete the multiple dependency claims.

An early and favorable action is earnestly solicited.

Respectfully submitted,



James V. Costigan
Registration No. 25,669

HEDMAN, GIBSON & COSTIGAN, P.C.
1185 Avenue of the Americas
New York, NY 10036-2646
(212) 302-8989

SULPHATED HYALURONIC ACID AND SULPHATED DERIVATIVES THEREOF COVALENTLY BOUND TO POLYURETHANES, AND THE PROCESS FOR THEIR PREPARATION

Field of the invention

5 The present invention concerns a polyurethane covalently bound to sulphated hyaluronic acid or to its sulphated derivatives, the process for their preparation, and the haemocompatible materials comprising said polyurethane.

State of the art

10 Considerable efforts have been made over the last few decades in the synthesis and surface modification of constantly new classes of polymers, in order to provide haemocompatible materials for the use in surgery.

Polyurethanes are widely used in biomedical applications because of their good mechanical and haemocompatible properties.

15 In order to enhance the latter property, molecules able to inhibit the coagulative process have been bound to the surface of polyurethane.

These substances are usually chosen from among those which can prevent platelet adhesion and aggregation, or block coagulation factors.

20 Heparin is one of the modifying agents used, and it can be bound to the polymer surface by both ionic bonds (US 4,944,767) and covalent bonds (W. Marconi et al., *Makromol. Chem.* 194, 1347-1356, 1993).

These bonds can be achieved once the polymer surface has been chemically modified by introducing reactive groups such as carboxy, hydroxy and amino groups.

25 However, one of the main drawbacks to the use of heparin is its high degradation rate on account of the enzyme heparinase, which limits its possible applications in fields of surgery such as cardiovascular surgery, which may call for the implant of devices where the absence of thrombogenicity must be guaranteed for lengthy periods.

30 Other modifying agents with anticoagulant properties are O-sulphated hyaluronic acid and its O-sulphated derivatives, prepared according to the method described in the international patent application by the Applicant, No. WO 95/25751.

Also of considerable importance are N-sulphated hyaluronic acid and its N-sulphated derivatives, optionally salified, wherein the glucosamines are partially N-sulphated or partially N-sulphated and partially or totally O-sulphated in position 6, as described in the international patent application by the Applicant No. WO 98/45335.

These sulphated derivatives have anticoagulative, non-thrombogenic, antiviral and anti-inflammatory properties, and it has been demonstrated that they inhibit platelet adhesion, aggregation and activation.

Moreover, the sulphated derivatives prove particularly advantageous in resisting the enzyme hyaluronidase, and they therefore ensure anticoagulant activity for far longer than heparin (G. Abatangelo et al., *Biomaterials* 18, 1997, 1411-1415).

However, not all the above derivatives as such cannot be processed in the form of biomaterials because the higher is the percentage of sulphation, the greater is their hydrophilia.

Therefore the need of novel bio- and haemocompatible compounds, which also have the advantageous properties of the sulphated hyaluronic acid and derivatives thereof, and can be used as such for the preparation of biomaterials and for the coating of biomedical objects, is deeply felt.

Summary of the invention

The present invention relates to polymers with a high degree of biocompatibility and haemocompatibility, constituted by a polyurethane bound covalently to a sulphated hyaluronic acid and derivatives thereof.

Said polymers maintain the mechanical characteristics (resistance to wear and tear, bending, elasticity, etc.) and the stability of polyurethane, also showing the anticoagulant activity, the effectiveness in inhibiting platelet adhesion, activation and aggregation, and the resistance to hyaluronidase of the sulphated hyaluronic acid and of the sulphated derivatives thereof.

Moreover, the derivatives according to the present invention, constituted by a polyurethane bound covalently to sulphated hyaluronic acid or its sulphated derivatives, show the considerable advantage of being easily mobilised on the polymer surface of biomedical objects, in most cases exploiting solubility in

organic solvents.

Indeed, the surface of an object made of polymeric material can be treated with the organic solution of the derivative triggering solubilization of the outer layers of the polymer and, due to the subsequent evaporation of the solvent, the derivative
5 adheres to the surface, merging with the polymer material of which the object is made.

In view of the foregoing the present invention further relates to haemocompatible materials containing the polyurethane bound covalently to the sulphated hyaluronic acid or sulphated hyaluronic acid derivatives.

10 The present invention further relates to industrial or medical articles or devices coated with haemocompatible materials comprising the polyurethane bound covalently to the sulphated hyaluronic acid or sulphated hyaluronic derivatives.

Brief description of the drawings

Figure 1 shows the infra-red spectra of the O-sulphated hyaluronic acid with a
15 degree of sulphation of 3.5, and of its polyurethane derivative in the dry and wet forms, as obtained in Example 1.

Figures 2, 3 and 4 show the SEM (Scanning Electron Microscope ; magnification = 1022x) images of the platelet adhesion test on the polyurethane derivative of O-sulphated hyaluronic acid obtained in Example 1.

Detailed description of the invention

By sulphated hyaluronic acid and sulphated hyaluronic acid derivatives we mean :

A₁) O-sulphated hyaluronic acid, and

A₂) O-sulphated hyaluronic acid derivatives,

both types being disclosed in WO 95/25751, we incorporate herewith by
25 reference ;

B₁) N-sulphated hyaluronic acid, and

B₂) N-sulphated hyaluronic acid derivatives,

both types being disclosed in WO 98/45335, we incorporate herewith by
reference.

30 In the O-sulphated derivatives of hyaluronic acid or hyaluronic acid derivatives of class A₁ and A₂ the number of O-sulphated groups is generally comprised

between 0.5 and 3.5.

In the N-sulphated hyaluronic acid B₁ or in the N-sulphated hyaluronic acid derivatives B₂ the glucosaminic portions of the repeating unit may be :

a) partially N-sulphated,

5 b) partially N-sulphated and partially O-sulphated, or

c) partially N-sulphated and totally O-sulphated,

wherein :

a) means a product obtained by means of a controlled sulphation reaction of the previously deacylated amino groups of glucosamine,

10 b) and c) mean a product obtained by a sulphation reaction in which, besides the previously mentioned deacylated amino groups of glucosamine, also the primary hydroxy functions of the same residue are involved, partially or totally respectively.

The hyaluronic acid derivatives used to prepare the sulphated compounds of classes A₂ and B₂ are selected among :

- 15 • the partial esters of hyaluronic acid containing at least one free carboxylic function and the remaining carboxylic functions being esterified with alcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic and heterocyclic series,
- the partial crosslinked esters containing at least one free carboxylic function and the remaining carboxylic functions being esterified with the alcoholic
- 20 function of the same hyaluronic acid chain or of a different chain like those disclosed in USP No. 5,676,964, we incorporate herewith by reference,
- the partial crosslinked esters disclosed in USP No. 4,957,744 we incorporate herewith by reference containing at least one free carboxylic function and the remaining carboxylic functions reacted with a polyalcohol of the aliphatic,
- 25 aromatic, arylaliphatic, heterocyclic series, and wherein a crosslinking is thereafter generated by means of spacer chains.

Any biocompatible polyurethane may be used for preparing the polyurethane bound covalently to sulphated hyaluronic acid. Preferred is the polyurethane present on the market with the trademark Pellethane®; particularly preferred is the

30 polyurethane having an average molecular weight of 180000 Da, this polymer containing the repeating unit 4,4'-methylenebis (phenyl isocyanate).

The haemocompatible materials according to the present invention besides polyurethane bound covalently to sulphated hyaluronic acid may optionally further contain natural, synthetic or semisynthetic polymers and/or pharmaceutically active substances.

- 5 The pharmaceutically active substances that can be used are, for example, antibiotics, anti-infective, antimicrobial, antiviral, cytostatic, antitumoral, anti-inflammatory and wound healing agents, anaesthetics, cholinergic or adrenergic agonists and antagonists, antithrombotic, anticoagulant, haemostatic, fibrinolytic, thrombolytic agents, proteins and their fragments, peptides, polynucleotides, growth factors, enzymes and vaccines.

10 Among the natural polymers, it is possible to use, for example, collagen, coprecipitates of collagen and glycosamino glycans, cellulose, polysaccharides in the form of gels such as chitin, chitosan, pectin or pectic acid, agar, agarose, xanthane, gellan, alginic acid or alginates, polymannan or polyglycans, starch and natural gums.

15 The semisynthetic polymers, for example, can be chosen from the group consisting of collagen crosslinked with agents such as aldehydes or precursors of the same, dicarboxylic acid or the halides thereof, diamines, derivatives of cellulose, hyaluronic acid, chitin or chitosan, gellan, xanthane, pectin or pectic acid, polyglycans, polymannan, agar, agarose, natural gum and glycosamino glycans.

20 Lastly, among the synthetic polymers it is possible to use, for example, polylactic acid, polyglycolic acid or copolymers of the same or their derivatives, polydioxanes, polyphosphazenes, polysulphonic resins and PTFE.

- 25 The haemocompatible materials according to the present invention are preferably in the form of sponges, films, membranes, threads, tampons, non-woven fabrics, microspheres, nanospheres, gauzes, gels and guide channels.

The haemocompatible materials according to the present invention can be used in the cardiovascular field or in any application involving contact with the blood or with highly vascularised body tissues.

30 The above haemocompatible materials can be used to advantage in various

surgical fields, in internal, osteoarticular, neurological, anastomotic, viscoelastic, ophthalmic, oncological, aesthetic, plastic, otorhinolaryngological, abdominal-pelvic, urogynaecological and cardiovascular surgery, in the prevention of post-surgical adhesions and in the prevention of hypertrophic scarring.


- 5 The haemocompatible materials according to the present invention can be used, besides in the surgical field, in haemodialysis, in cardiology, in dermatology, in ophthalmology, in otorhinolaryngology, in dentistry, in gynaecology, in urology and in extracorporeal blood circulation and oxygenation.

The above haemocompatible materials in their various forms can also be used to
10 advantage as cell culture supports, such as for mesenchymal cells or mature cells to obtain connective, glandular and nerve tissue.


The haemocompatible materials can also be used in the processes of preparation and coating of articles or devices to be used both in the medical field and in industry, which show, due to this coating, biological characteristics on the
15 surfaces.

The objects that can be coated are, for example, catheters, guide channels, probes, cardiac valves, soft tissue prostheses, prostheses of animal origin such as cardiac valves from pigs, artificial tendons, bone and cardiovascular replacements, contact lenses, blood oxygenators, artificial kidneys, hearts,
20 pancreases and livers, blood bags, syringes, surgical instruments, filtration systems, laboratory instruments, containers for cultures and for the regeneration of cells and tissues, supports for peptides, proteins and antibodies.

Particularly preferred polyurethane bound covalently to sulphated hyaluronic acid are those characterised by the following formula (I)



and formula (II)




5

wherein PU is a residue of the polyurethane chain, and Hsulph is a residue of sulphated hyaluronic acid as in the above classes A₁ and B₁, or a sulphated hyaluronic acid derivative containing at least one free carboxylic function as in the above classes A₂ and B₂.


10 In particular, the process for preparing the polyurethane bound covalently to sulphated hyaluronic acid of formula (I) is obtained with a process comprising the following steps :

i) the polyurethane (IV) is reacted with bromoacetic acid (VII) in the presence of N,N'-dicyclohexylcarbodiimide (DCC), to obtain the adduct of formula (III)

according to the following reaction scheme :





5



ii) the adduct (III) coming from step i) is reacted with $\text{HOOC}-\text{Hsulph}$ wherein Hsulph has the above meanings, thereby obtaining the compound of formula (I) according to the following scheme :

10





The reaction in step i) is typically carried out in an inert atmosphere and in an organic solvent, preferably in dimethylformamide (DMF).


- 5 Before carrying out step ii) the reaction mixture coming from step i) is preferably filtered to separate the solution containing the desired product (III) from the precipitate of dicyclohexylurea which forms simultaneously.

Step ii) is preferably carried out in the presence of sodium bicarbonate.


- 10 The reaction in step ii) is typically carried out in 24 hours at a temperature ranging from 25 to 45°C, and preferably at 25°C.

The polyurethane derivative of formula (II) can be obtained by a process comprising the following steps :




- i') a sulphated hyaluronic acid or a sulphated hyaluronic acid derivative, wherein part or all of the carboxy groups of the glucuronic residue are in their acid form
- 15 $\text{HOOC}-\text{Hsulph}$ is reacted with hexamethylenediisocyanate (HMDI) (V), to obtain the adduct of formula (VI)



10



ii') the adduct (VI) coming from step i') is reacted with the polyurethane (IV) to obtain the desired product (II) according to the following scheme :



10

Both reactions in steps i') and ii') are typically carried out in an inert atmosphere,

by using DMF as the solvent.

The temperature in step ii') is kept in the range from 45 to 55°C for a time from 48 to 72 hours, while the mixture is left to react.

The following examples are given to provide non-limiting illustrations of the present invention.

EXAMPLE 1

Polyurethane covalently bound to O-sulphated hyaluronic acid of formula (I) (PUBRAC-1)

30 ml of a 10% (w/v) solution in DMF of Pellethane® are supplemented with 1.5 g of DCC while stirring.

Once the DCC has dissolved, 1.8 g of bromoacetic acid dissolved in a minimal quantity of DMF are added drop by drop.

After approximately 30 minutes the solution is filtered to separate it from the white dicyclohexylurea precipitate.

1 g of O-sulphated hyaluronic acid sodium salt (molecular weight 200 kDa and degree of sulphation 3.5) is dissolved in 60 ml of water, and this solution has percolated along the length of a ion exchange column, packed with 75 ml of a sulphonic resin in the form of tetrabutylammonium salt.

This resin has been prepared by the means of activation of a protonated sulphonic resin with a tetrabutylammonium hydroxide 40% w/v solution.

The solution containing the O-sulphated hyaluronic acid tetrabutylammonium salt coming from the column has been collected, then freeze dried.

200 mg of the so-obtained O-sulphated hyaluronic acid tetrabutylammonium salt and 2 g of sodium bicarbonate are added to the above polyurethane solution in DMF.

The mixture is left to react for 24 hours while being stirred at a temperature of 25°C.

If any precipitate has formed the reaction mixture is filtered again, then cast in Petri dishes.

We report hereafter in Figure 1 the infra-red spectra of the sulphated hyaluronic acid with a degree of sulphation of 3.5, and of its polyurethane derivative in the

dry and wet forms, obtained as above illustrated.

The polyurethane derivative in its dry state presents the typical spectrum of polyurethane not modified with sulphated hyaluronic acid, whereas in its wet state, peaks of between 3600 and 2800 cm^{-1} and at 1654 cm^{-1} can be seen as relative to the functional groups of the sulphated hyaluronic acid.

EXAMPLE 2

Polyurethane covalently bound to N-sulphated hyaluronic acid of formula (I) (PUBRAC-2)

30 ml of a 10% (w/v) solution in DMF of Pellethane® are supplemented with 1.5 g of DCC under stirring.

Once the DCC has dissolved, 1.8 g of bromoacetic acid dissolved in a minimal quantity of DMF is added drop by drop.

30 to 40 minutes later, the solution is filtered to separate it from the white precipitate of dicyclohexylurea.

This solution is supplemented with 2 g of sodium bicarbonate and 200 mg of N-sulphated hyaluronic acid tetrabutylammonium salt obtained starting from N-sulphated hyaluronic acid sodium salt (molecular weight 200 KDa and 30% sulphation) as described in Example 1 for the corresponding O-sulphated compound.

The reaction mixture is then left to react for 24 hours under stirring at a temperature of 25°C.

It is filtered again, and then cast in Petri dishes.

EXAMPLE 3

Polyurethane covalently bound to O-sulphated hyaluronic acid of formula (I) (PUBRAC-3)

2 g of DCC are added in an inert atmosphere to 25 ml of a 10% (w/v) solution in DMF of Pellethane® while stirring.

Once the DCC has dissolved, 1.8 g of bromoacetic acid dissolved in a minimal quantity of DMF are added drop by drop.

After approximately 30 minutes the solution is filtered to separate it from the white precipitate of dicyclohexylurea.

To the so-obtained solution 250 mg of O-sulphated hyaluronic acid tetrabutylammonium salt, prepared starting from the corresponding sodium salt (molecular weight 200 KDa and degree of sulphation 3.5) as described above in Example 1, and 2 g of sodium bicarbonate are added, then the mixture is left to
5 react for 24 hours while being stirred at a temperature of 45°C.

If any precipitate has formed the reaction mixture is filtered again, then cast in Petri dishes.

EXAMPLE 4

**Purification of polyurethane covalently bound to sulphated hyaluronic acid
10 of formula (I) obtained according to Example 3 (PUBRAC Ris THF)**

The preparation procedure as described in Example 3 is carried out once again, but the reaction product is dissolved in THF before cast in Petri dishes.

EXAMPLE 5

**Purification of polyurethane covalently bound to sulphated hyaluronic acid
15 of formula (I) obtained according to Examples 1-4 (PUBRAC)**

Before cast in Petri dishes, the reaction product as obtained in Examples 1-4 is first washed with acetone, then 2-3 washing with a 10% solution of NaCl are performed.

EXAMPLE 6

20 Polyurethane covalently bound to O-sulphated hyaluronic acid of formula (II) (PUHMDI-6)

O-sulphated hyaluronic acid is obtained starting from the corresponding sodium salt (molecular weight 200 kDa and degree of sulphation 3.5) as described above in Example 1, and a complete protonation of its carboxy group is performed
25 bringing the tetrabutylammonium salt solution coming from the column to pH = 3-4, before freeze drying.

300 mg of the so-obtained O-sulphated hyaluronic acid are dissolved in the minimal quantity of DMF (approximately 10 ml).

Once solubilization is complete, the solution is placed in a flask containing 200 µl
30 of HMDI under stirring and in an inert atmosphere.

30 minutes later, 10 ml of a 10% (w/v) Pellethane® solution in DMF are added.

The solution is left under stirring and in an inert atmosphere at a temperature of 45-50°C for 3 days. It is then cast in Petri dishes.

EXAMPLE 7

Polyurethane covalently bound to O-sulphated hyaluronic acid of formula (II) (PUHMDI-7)

O-sulphated hyaluronic acid is obtained starting from the corresponding sodium salt (molecular weight 200 kDa and degree of sulphation 3.5) as described above in Example 1, and a complete protonation of its carboxy group is performed bringing the tetrabutylammonium salt solution coming from the column to pH = 3-4, before freeze drying.

250 mg of the so-obtained O-sulphated hyaluronic acid are dissolved in the minimal quantity of DMF (approximately 10 ml), then the solution is poured under stirring and in an inert atmosphere into a flask containing 200 µl of HMDI.

30 minutes later, 25 ml of a 10% (w/v) solution in DMF of Pellethane® are added to the reaction mixture preserving an inert atmosphere.

The solution is left under stirring and in an inert atmosphere at a temperature of 55°C for 48 hours. It is then cast in Petri dishes.

EXAMPLE 8

Purification of polyurethane covalently bound to O-sulphated hyaluronic acid of formula (II) obtained according to Examples 6 and 7 (PUHMDI)

Before cast in Petri dishes, the reaction product as obtained in Examples 6 and 7 is washed with a 10% solution of NaCl for 2-3 times.

EXAMPLE 9

Test of platelet adhesion on the material obtained according to Example 1 (PUBRAC-1).

Blood was drawn from a healthy, non-smoking donor who had taken no drugs for a fortnight before. Platelet-rich plasma (PRP) was obtained by centrifuging the whole blood at 250 rpm for 25 minutes at room temperature.

1 ml of PRP was placed in contact with each sample (0.5 cm x 0.5 cm) of the test polymer and these were then left for 3 hours at room temperature in order to favour platelet adhesion. The samples were then washed in PBS (phosphate

buffer solution) to remove any platelets which had not adhered to the surface, and then incubated in a solution of glutaraldehyde at 2.5% (v/v) in 100 mM sodium cacodylate for 30 seconds.

Subsequently, the films were washed in cacodylate of sodium, 100 mM, for 30 seconds, rinsed in distilled water and left in the first dehydrating solution (70% v/v of ethanol in distilled water) for 15 minutes. The samples were then transferred to the second dehydrating solution (90% v/v of ethanol in distilled water) for 15 minutes and lastly in absolute ethanol for another 15 minutes.

All the samples were then dehydrated in a vacuum for 12 hours, metallized with gold and analysed with a scanning electron microscope (SEM) (Figures 2, 3 and 4).

As can be seen from figures 2, 3 and 4, the surface of the material is morphologically irregular and characterised by the presence of numerous slits of varying sizes. Despite these irregularities, 90% of the material presents no phenomena of platelet adhesion.

Only on the remaining 10% of the surface can the presence of platelets be observed, which in some cases form small clusters while in others they appear to maintain their individual character even though they have lost the discoid shape typical of non-activated platelets, and they have extruded pseudopods with which they cling to the surface.

EXAMPLE 10

Test of whole blood coagulation on the material obtained according to Examples 3 (PUBRAC-3) and 4 (PUBRAC Ris THF).

This test was performed on PUBRAC-3 and PUBRAC Ris THF using blood from a single donor.

5 ml of blood was placed in contact with a sample (0.5 cm x 0.5 cm) of the following materials :

control	polystyrene
PU	Pellethane®
PUBRAC-3	polyurethane derivative according to Example 3
PUBRAC Ris THF	polyurethane derivative according to Example 4

The samples were left at room temperature and the time necessary to achieve blood coagulation is then measured.

The results are reported in the following table :

5 Table 1

SAMPLE	COAGULATION TIME (minutes)
Control (polystyrene)	25 ± 2
PU	26 ± 2
PUBRAC-3	> 120
PUBRAC Ris THF	> 120

Table 1 shows that the polyurethane derivatives according to the present invention have an anticoagulant activity at least equal to that of polyurethane, and even much higher than that for the polyurethane derivative obtained according to Example-3, which shows a coagulation time getting over 2 hours.

EXAMPLE 11

Thrombin time measured by using the material obtained according to Example 3 (PUBRAC-3) and 7 (PUHMDI-7).

The ability of the derivatives according to the present invention in increasing blood coagulation time is measured by the thrombin time test conducted with a coagulometer.

An assessment is made of the time it takes to transform fibrinogen into fibrin after the addition of an excess of thrombin in a blood sample in the presence of the polymer. A result of over 120 seconds is no longer significant.

The results are reported in the following table:

Table 2

SAMPLES	THROMBIN TIME (seconds)
Control (polystyrene)	12.1 ± 0.9
PU	12.5 ± 0.4
PUBRAC-3 air side (\varnothing 0.8 cm)	> 120
PUBRAC-3 glass side (\varnothing 0.8 cm)	> 120
PUBRAC-3 glass side (0.8 cm x 0.5 cm)#	26.2 ± 3.8
PUBRAC-3 air side (0.8 cm x 0.5 cm)#	15.2 ± 0.2
PUHMDI-7(0.8 cm x 0.5 cm)	16.3 ± 0.2

thrombin time determined on plasma after 10 minutes contact with the polyurethane derivative at 37°C

The table shows that the anticoagulant activity occurs on the side of the film which is in contact with the glass because the polar environment causes the sulphated hyaluronic acid group to be exposed on the surface, while different results are observed on the side which is in contact with the air.

EXAMPLE 12

Reptilase time measured by using the material obtained according to Examples 3 (PUBRAC-3) and 4 (PUBRAC Ris THF).

Reptilase, a fraction extracted from the venom of the South American snake *Bothrox atrox*, is an enzyme that clots fibrinogen by splitting off its fibrinopeptide A.

The reptilase time is determined by incubating 0.3 ml of human plasma on the round samples (diameter 0.8 cm) of PUBRAC-3 and PUBRAC Ris THF at 37 °C for 2 minutes, then adding Reptilase Reactive (function of thrombin extracts from *Bothrox Atrox* venom, Haemodiagnostica Diagnostica Stago, Boehringer Mannheim), and measuring the clotting time automatically (Elvi Digiclot 2 Coagulometer, Logos S.p.A., Milan, Italy). Table 3 shows the effects of the materials obtained according to Examples 3 and 4 on reptilase time.

Table 3

SAMPLE	REPTILASE TIME
Control (polystyrene)	16.20 \pm 0.05
PUBRAC-3	15.2 \pm 0.2
PUBRAC Ris THF	16.65 \pm 0.05

The data in Table 3 show that the materials obtained according to Examples 3 and 4 have moderate and not very significant effects on reptilase time.

EXAMPLE 13

Thrombin inhibition measured by using the material obtained according to Example 3 (PUBRAC-3)

The thrombin inhibition in plasma and in the presence of purified molecules, i.e. antithrombin III (AT III) and heparin cofactor (HC II), were studied for the material as obtained in Example 3 (PUBRAC-3), in order to investigate the manner in which the derivatives of the present invention exert their anticoagulant activity.

Selected donors were normal, healthy subjects who had fasted for more than 8 hours and had not taken any medication for at least 14 days.

Blood samples were drawn in 3.8% (w/v) tri-sodium citrate as anticoagulant at a ratio of 9 parts blood to 1 part citrate. The samples were centrifuged at 3500 rpm for 15 minutes to obtain platelet poor plasma (PPP). Pooled citrated plasma was prepared from 10-12 normal drug free volunteers and stored in aliquots at -80°C.

AT III (1 U.I./ml) and HC II (Heparin Cofactor II purchased by Calbiochem, USA) were reconstituted from lyophilised powder with sterile water and used immediately. 32.4 mg of human fibrinogen (molecular weight \approx 341,000, Calbiochem, USA) was dissolved in 6 ml of a physiological solution (0.9% NaCl, pH = 7.4), then 0.2 ml of this solution were placed in contact with a sample of PUBRAC-3 (\varnothing 0.7 cm).

0.2 ml of AT III or 0.2 ml of HC II or 0.2 ml of PBS was then added to the above sample.

The thrombin time with or without AT III and HC II was determined manually by adding 0.2 ml of thrombin (Human Thrombin purchased by Boheringer Mannheim, Germany) to 0.2 ml of the above samples.

The results are summarised in the following table :

Table 4

SAMPLE	Thrombin Time (sec.) without AT III and HC II	Thrombin Time (sec.) with AT III	Thrombin Time (sec.) with HC II
PU	8.4 ± 0.4	8.1 ± 0.2	18.5 ± 1.3
PUBRAC-3	67.3 ± 3.3	63.3 ± 3.3	> 120

The above experiment was performed both with and without AT III and the results obtained were approximately the same in both cases, thus demonstrating that presumably the inactivation of thrombin by the polyurethane derivatives of the present invention is not mediated by AT III.

Moreover, the above results show the ability of the present derivatives to accelerate the thrombin inhibition mediated by HC II.

In conclusion, the thrombin was inhibited by the present polyurethane derivatives both via HC II and via direct interaction.

CLAIMS

1 1. A polyurethane bound covalently to sulphated hyaluronic acid or to a sulphated
2 hyaluronic acid derivative.

1 2. The polyurethane according to claim 1, wherein the starting polyurethane
2 comprises the repeating unit 4,4'-methylenebis (phenyl isocyanate).

1 3. The polyurethane according to any of claims 1 and 2, wherein the starting
2 sulphated hyaluronic acid is selected from the group consisting of :

3 A₁) O-sulphated hyaluronic acid, and

4 B₁) N-sulphated hyaluronic acid.

1 4. The polyurethane according to any of claims 1 and 2, wherein the starting
2 sulphated hyaluronic acid derivative is selected from the group consisting of :

3 A₂) O-sulphated hyaluronic acid derivative, and


4 B₂) N-sulphated hyaluronic acid derivative.

1 5. The polyurethane according to claim 4, wherein the hyaluronic acid derivatives
2 used to prepare the starting sulphated hyaluronic acid A₂ and B₂ are selected from
3 the group consisting of :


- 4 • the partial esters of hyaluronic acid containing at least one free carboxylic
5 function and the remaining carboxylic function esterified with alcohols of the
6 alifatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series,
- 7 • the partial crosslinked esters containing at least one free carboxylic function
8 and the remaining carboxylic functions are esterified with the alcoholic function
9 of the same hyaluronic acid or of a different chain,
- 10 • the partial crosslinked esters containing at least one free carboxylic function
11 reacted with a polyalcohol of the aliphatic, aromatic, arylaliphatic, heterocyclic
12 series, and wherein crosslinking is thereafter generated by means of spacer
13 chains.

1 6. The polyurethane according to any of claims 1-5 of formula (I)

21



or formula (II)



wherein PU is a residue of the polyurethane chain, Hsulph is a residue of the sulphated hyaluronic acid or a sulphated hyaluronic acid derivative containing at least one free carboxylic function.

7. A process for preparing the polyurethane of formula (I) comprising the following steps :

- i) the polyurethane (IV) is reacted with bromoacetic acid (VII) in the presence of N,N'-dicyclohexylcarbodiimide (DCC), to obtain the adduct of formula (III) ;
- ii) the adduct (III) coming from step i) is reacted with HOOC—Hsulph, thereby

6 obtaining the compound of formula (I).

1 8. A process for preparing the polyurethane of formula (II) comprising the following
2 steps :

3 i') HOOC—Hsulph is reacted with hexamethylenediisocyanate (HMDI) (V), to
4 obtain the adduct of formula (VI) ;

5 ii') the adduct (VI) coming from step i') is reacted with the polyurethane (IV) to
6 obtain the desired product (II).

1 9. Haemocompatible material comprising at least one polyurethane according to
2 any of claims 1-6.

1 10. Haemocompatible material consisting of at least one polyurethane according
2 to any of claims 1-6.

1 11. The haemocompatible material according to claim 9, further comprising a
2 pharmaceutically active substance.

1 12. The haemocompatible material according to claim 11, wherein said
2 pharmaceutically active substance is selected from the group consisting of
3 antibiotics, antiinfective, antimicrobial, antiviral, cytostatic, antitumoral, anti-
4 inflammatory, wound healing agents, anaesthetics, cholinergic or adrenergic
5 agonists or antagonists, antithrombotic, anticoagulant, haemostatic, fibrinolytic,
6 thrombolytic agents, proteins or their fragments, peptides, polynucleotides, growth
7 factors, enzymes and vaccines.

1 13. The haemocompatible material according to any of claims 9, 11 and 12,
2 further comprising at least one natural, synthetic or semisynthetic polymer.

1 14. The haemocompatible material according to claim 13, wherein said natural
2 polymer is selected from the group consisting of collagen, collagen coprecipitates
3 and glycosamino glycans, cellulose, polysaccharides in the form of gels such as
4 chitin, chitosan, pectin or pectic acid, agar, agarose, xanthane, gellan, alginic acid
5 or the alginates, polymannan or polyglycans, starch and natural gums.

1 15. The haemocompatible material according to claim 13, wherein said
2 semisynthetic polymer is selected from the group consisting of collagen
3 crosslinked with agents such as aldehydes or precursors of the same, dicarboxylic
4 acids or their halides, diamines, derivatives of cellulose, hyaluronic acid, chitin or


5 chitosan, gellan, xanthane, pectin or pectic acid, polyglycans, polymannan, agar,
6 agarose, natural gum and glycosamino glycans.

1 16. The haemocompatible material according to claim 13, wherein said synthetic
2 polymer is selected from the group consisting of polylactic acid, polyglycolic acid
3 or copolymers of the same or their derivatives, polydioxanes, polyphosphazenes,
4 polysulphonic resins and PTFE.

1 17. The haemocompatible material according to any of claims 9-16, in the form of
2 sponges, films, membranes, threads, tampons, non-woven fabrics, microspheres,
3 nanospheres, gauzes, gels and guide channels.

1 18. Industrial or medical articles or devices made with or coated with the
2 haemocompatible material according to any of claims 9-16.

1 19. The industrial or medical articles or devices according to claim 18, wherein
2 said devices are selected from the group consisting of catheters, guide channels,
3 probes, cardiac valves, soft tissue prostheses, prostheses of animal origin such as
4 cardiac valves from pigs, artificial tendons, bone replacements or cardiovascular
5 prostheses, contact lenses, blood oxygenators, artificial kidneys, hearts, pancreas
6 and livers, blood bags, syringes, surgical instruments, filtration systems, laboratory
7 instruments, containers for cultures and for cell and tissue regeneration, supports
8 for peptides, proteins and antibodies.






Figure 2

Figure 3





Figure 4



Docket No: _____

40137200

**APPLICATION FOR UNITED STATES LETTERS PATENT
DECLARATION, POWER OF ATTORNEY, AND PETITION**

As a below-named inventor, I declare that:

My residence, post office address and citizenship are as stated next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the invention which is described and which is claimed in the specification, entitled: SULPHATED HYALURONIC ACID AND SULPHATED DERIVATIVES THEREOF COVALENTLY BOUND TO POLYURETHANES...

The specification [] is attached hereto [X] was filed on 11 AUG 22 2000, as Application Serial No. 09/622,146.

- ☒ was filed as PCT international application
Number PCT/EP99/01191
on 24 February 1999
and was amended under PCT Article 19
on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of said specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.¹

COUNTRY	APPLICATION NUMBER	DATE (Day, Month, Year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119	
ITALY	PD98A000037	25 February 1998	Yes [X]	No []
			Yes []	No []

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

¹In Non-Convention cases, a listing of all filings and current status of cases filed more than a year before the U.S. filing is required to comply with 37 CFR 1.56(a). Such a listing may be attached.

APPLICATION SERIAL NO.	FILING DATE	STATUS

I hereby appoint my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the U.S. Patent & Trademark Office connected therewith:

Edward A. Hedman, Reg. No. 22,120; Thomas M. Gibson, Reg. No. 24,638;
James V. Costigan, Reg. No. 25,669; Kenneth F. Florek, Reg. No. 33,173;
7 Alan B. Clement, Reg. No. 34,563; Martin P. Endres, Reg. No. 35,498 and
Timothy X. Gibson, Reg. No. 40,618.

CORRESPONDENCE AND CALLS TO: James V. Costigan, Esq.
HEDMAN, GIBSON & COSTIGAN, P.C.
1185 Avenue of the Americas
New York, NY 10036-2601
Telephone: (212) 302-8989

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR (S)	DATE	RESIDENCE AND P.O. ADDRESS
Name: <u>BARRUCCI Rolando</u> Signature: <i>[Signature]</i>	Date: 23 November 2000 Citizen of: ITALY	Via Primo Simi 1 53010 <u>LUCIGNANO D'ARBIA</u> - ITALY ITX
Name: <u>CONSUMI Marco</u> Signature: <i>[Signature]</i>	Date: 23 November 2000 Citizen of: ITALY	S. Eugenia 83 53100 <u>SIENA</u> - ITALY ITX
Name: <u>MAGNANI Agnese</u> Signature: <i>[Signature]</i>	Date: 23 November 2000 Citizen of: ITALY	Località Agresto 391 53010 <u>S. ROCCO A PILLI</u> ITX - ITALY
Name: <u>CALLEGARO Lanfranco</u> Signature: <i>[Signature]</i>	Date: 23 November 2000 Citizen of: ITALY	Via Monte Grappa 6 36016 <u>THIENE</u> - ITALY